r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.

Active Comparator: 1500

r-HuEPO administered at 1500 hrs

Drug: r-HuEPO

r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.

Active Comparator: 2200

r-HuEPO administered at 2200 hrs

Drug: r-HuEPO

r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.

Detailed Description:

This phase-II crossover study was designed to test if the activity of erythropoietin is time dependent. Patients with chronic renal failure on hemodialysis requiring r-HuEPO to maintain adequate levels of hematocrit are eligible for the study. Patients were administered r-HuEPO subcutaneously three times per week, 50 U/kg, rounded to the nearest 2000 units. r-HuEPO will be administered until the hematocrit rises from the baseline level of 20-24% to the target level of 30-34%. This will be repeated three times, each at different times of day, either 0800, 1500 or 2200 hrs and the order of these will be randomly determined. Each patient will complete all three of the phases.

Other disorders that may diminish the response of the bone marrow to r-HuEPO

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00744445